Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar

Laurus Labs informs about company updates

05 Sep 2019

Laurus Labs has informed that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019. And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy). A press release to this extent is enclosed.

The above information is a part of company’s filings submitted to BSE.

Related Laurus Labs Ltd. Links:

Laurus Labs Share Price

651.30 3.75 (0.58%) Jul 26, 18:02
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 703.55
Dr. Reddy's Lab 5409.15
Lupin 1171.65
Cadila Healthcare 607.10
Aurobindo Pharma 952.95
View more..
Sensex vs Laurus Labs
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback